Key result
Elevated NT-proBNP plasma levels independently predicted a future diagnosis of cancer in patients with coronary artery disease (HR 1.030 per 100 pg/ml increase).
Cohort (n=699)
Yes
Elevated NT-proBNP plasma levels independently predict a future diagnosis of cancer in patients with stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
Does not support NT-proBNP-guided cancer screening in CAD; hypothesis-generating association requires prospective confirmation.
OBJECTIVE: Several papers have reported elevated plasma levels of natriuretic peptides in patients with a previous diagnosis of cancer. We have explored whether N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels predict a future diagnosis of cancer in patients with coronary artery disease (CAD). METHODS: We studied 699 patients with CAD free of cancer. At baseline, NT-proBNP, galectin-3, monocyte chemoattractant protein-1, soluble tumor necrosis factor-like weak inducer of apoptosis, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin I plasma levels were assessed. The primary outcome was new cancer diagnosis. The secondary outcome was cancer diagnosis, heart failure requiring hospitalization, or death. RESULTS: After 2.15±0.98 years of follow-up, 24 patients developed cancer. They were older (68.5 [61.5, 75.8] vs 60.0 [52.0, 72.0] years; p=0.011), had higher NT-proBNP (302.0 [134.8, 919.8] vs 165.5 [87.4, 407.5] pg/ml; p=0.040) and high-sensitivity C-reactive protein (3.27 [1.33, 5.94] vs 1.92 [0.83, 4.00] mg/L; p=0.030), and lower triglyceride (92.5 [70.5, 132.8] vs 112.0 [82.0, 157.0] mg/dl; p=0.044) plasma levels than those without cancer. NT-proBNP (Hazard Ratio [HR]=1.030; 95% Confidence Interval [CI]=1.008-1.053; p=0.007) and triglyceride levels (HR=0.987; 95%CI=0.975-0.998; p=0.024) were independent predictors of a new cancer diagnosis (multivariate Cox regression analysis). When patients in whom the suspicion of cancer appeared in the first one-hundred days after blood extraction were excluded, NT-proBNP was the only predictor of cancer (HR=1.061; 95%CI=1.034-1.088; p<0.001). NT-proBNP was an independent predictor of cancer, heart failure, or death (HR=1.038; 95%CI=1.023-1.052; p<0.001) along with age, and use of insulin and acenocumarol. CONCLUSIONS: NT-proBNP is an independent predictor of malignancies in patients with CAD. New studies in large populations are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Tuñón et al. (2015) conducted a cohort in Coronary artery disease (CAD) (n=699). N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels was evaluated on New cancer diagnosis (HR 1.030, 95% CI 1.008-1.053, p=0.007). Elevated NT-proBNP plasma levels independently predicted a future diagnosis of cancer in patients with coronary artery disease (HR 1.030 per 100 pg/ml increase).
Synapse has enriched 10 related papers. Consider them for comparative context: